Home Blog Page 3310

Kangpu Biopharmaceuticals Received CDE Approval for Phase IIb Clinical Trial of KPG-818 in Moderate to Severe Cutaneous Manifestations of SLE

By
Advertorial Desk
-

HEFEI, China, April 28, 2025 /PRNewswire/ — Kangpu Biopharmaceuticals, Ltd. announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved Phase IIb clinical trial of KPG-818 capsule for the treatment of moderate to severe cutaneous manifestations of systemic lupus erythematosus (SLE).

About Cutaneous Manifestations of SLE

SLE is a complex, heterogeneous, inflammatory, chronic autoimmune disease in which the body’s immune system attacks its own tissues, including skin, joints, and kidneys. Skin is the second most frequently affected organ system of SLE. The majority of SLE patients experience cutaneous manifestations over the course of the disease. Cutaneous manifestations of SLE carries a significant burden with regard to psychosocial well-being and medical costs.

Treatment options for cutaneous manifestations of SLE are limited, and current therapies (e.g., glucocorticoids, antimalarials, immunosuppressants) often lack efficacy or carry systemic side effects. There are tremendous unmet medical needs for novel therapeutics, especially an oral agent.

About KPG-818

KPG-818 is a novel oral molecular glue modulator of the E3 ubiquitin ligase complex CRL4-CRBN. It demonstrated high binding affinity to CRBN and potent degradation of zinc-finger transcription factors Aiolos (IKZF3) and Ikaros (IKZF1). KPG-818 effectively regulates immune cells (B cells, T cells, and pDC cells) and the release of multiple cytokines, possessing immunomodulatory, anti-angiogenic and anti-tumor effects. In the Phase IIa clinical study in SLE patients completed in the US, KPG-818 was well tolerated and demonstrated promising preliminary efficacy in SLE patients with cutaneous manifestations. KPG-818 was well tolerated in healthy subjects in a Phase I clinical study completed in China. 

About Kangpu Biopharmaceuticals, Ltd.

Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative therapeutics for the treatment of solid tumors, hematologic malignancies, autoimmune diseases, and inflammatory disorders through novel solutions, including targeted protein degradation. Kangpu has developed a robust pipeline of potential first-in-class and best-in-class drug candidates based on proprietary technology platforms, including NeoMIDES®, gDACs®, and X-SYNERGY®.

For more information, please visit www.KangpuGroup.com.

Galaxy Macau Launches “Timeless Flavors of Macau” in Tributes to Local Culinary Heritage

By
Advertorial Desk
-

A Symphony of Authentic Macanese Flavors and Luxury Dining Experiences


MACAU SAR – Media OutReach Newswire – 28 April 2025 – Galaxy Macau™, a world-class luxurious integrated resort boasting over 120 dining offerings, is widely recognized as a gastronomic crossroads where global palates converge, presenting award-winning delicacies to guests from locals and global alike. Beyond its culinary diversity, the integrated resort turns its spotlight this season onto the launch of “Timeless Flavors of Macau,” showcasing Galaxy Macau’s commitment to supporting local SMEs, collaborating with time-honored Macanese brands to present a heartfelt tribute to the city’s culinary legacy. All while underscoring its endeavors to preserving Macau’s UNESCO Creative City of Gastronomy proivenance, while elevating the city’s dining scene to greater heights.

The culinary team at Waso Cafe have meticulously incorporated Pak Fa Fui’s beloved nostalgic dishes and drinks for a limited run.
The culinary team at Waso Cafe have meticulously incorporated Pak Fa Fui’s beloved nostalgic dishes and drinks for a limited run.

This series debuts with a collaboration between Waso Cafe, the iconic cha chaan teng, and Tong Iec Pak Fa Fui, a century-old purveyor of traditional preserves. The culinary team at Waso Cafe has meticulously incorporated Pak Fa Fui’s beloved products into exceptional dishes such as “Pork Ribs with Five Preserved Vegetables”, “Stir-Fried Noodles with Shredded Pork”, and “Braised Pork Belly in Waso Soft Bun”, creating a harmonious fusion of flavors to delight the senses. The beverage menu offers dazzling creative infusions of preserved fruits – think “Preserved Plum and Mulberry Herbal Tea”, “Soda with Dried Tangerine Peel and Dried Sweet Plum”, and “Sprite with Salted Lemon and Fresh Lemon” – a refreshing nostalgic ode to spring and summer. These six delicious creations are available for a limited time only.

Galaxy Macau also offers a diverse range of culinary experiences encompassing regional Chinese cuisines, including Northern, Sichuan, and Cantonese dishes. Each with expert tea sommeliers who are deeply versed in Chinese tea culture and earn coveted award titles at national competitions for their exceptional skills in the art of curating exclusive premium pairings. On May 15, Galaxy Macau is hosting the “The Art of Tea: Workshop and Dinner”, promising an immersive exploration of Chinese tea traditions led by the Champion of the 2018 National Competition for Tea Sommeliers, Mr. Andrew U. Guests will be joining the journey into tea by tasting nine rare teas, mastering basic brewing techniques, and gaining foundational knowledge of different tea varieties, with a curated tea set gift to take home. The evening will culminate at Pak Loh Chiu Chow Restaurant with a Tea-infused Cuisine and Tea Pairing Dinner, Savor the refreshing fragrance of Iron Buddha in his tender abalone, or immerse yourself in the pleasing jasmine notes in a crispy pigeon. Three award-winning tea masters will be at the dinner to present their selection of premium teas, with each brew telling a unique story. Guests will embark on a sensorial adventure by sipping, studying, brewing, and savoring, and finally immersing themselves in the refined artistry of Chinese tea culture.

On May 15, Galaxy Macau is hosting the "The Art of Tea: Workshop and Dinner”, promising an immersive exploration of Chinese tea traditions led by the Champion of the 2018 National Competition for Tea Sommeliers Mr. Andrew U.
On May 15, Galaxy Macau is hosting the “The Art of Tea: Workshop and Dinner”, promising an immersive exploration of Chinese tea traditions led by the Champion of the 2018 National Competition for Tea Sommeliers Mr. Andrew U.

Chef Ng Man Kin at Putien of Galaxy Macau redefines the globally acclaimed Fujian cuisine with deluxe flair. Adhering to authentic culinary traditions, the Chef meticulously selects precious ingredients to present a variety of delicious dishes. Seasonal standouts include Braised Fish Maw with Yong An Yellow Pepper – a fiery-sweet crescendo, featuring a spicy yellow pepper sauce with a smooth texture. The novel pairing of devilishly hot Yong An yellow pepper sauce with sea cucumber takes the premium delicacy to sensational heights. Marinated Shrimp in Fujian Wine, marinated in old wine for a smooth and tender taste. Braised Duck with Ginger, slow-cooked to aromatic perfection. The 12-hour-simmered Tong An Braised Pork Belly takes over guests’ taste buds owing rich and savory flavor, all the above showcase the kitchen’s technical brilliance. The restaurant also offers exclusive dishes and Southeast Asian-inspired creative delicacies in an elegant setting, dedicated to providing guests with a distinguished and cozy dining experience.

Chef Ng Man Kin at Putien of Galaxy Macau redefines the globally acclaimed Fujian cuisine with a luxe flair. Marinated Shrimp in Fujian Wine, marinated in aged wine for a smooth taste.
Chef Ng Man Kin at Putien of Galaxy Macau redefines the globally acclaimed Fujian cuisine with a luxe flair. Marinated Shrimp in Fujian Wine, marinated in aged wine for a smooth taste.

Meanwhile at Hotel Okura Macau, Nagomi embodies thoughtful Japanese hospitality at its finest. From now until May 28, Nagomi presents a Sakura-themed feast. Desserts feature the delicate elegance of cherry blossom intertwined with fragrant peach and the subtle bitterness of matcha, while the refreshing combination of fragrant sakura tea cake and sour cherry compote spotlights the vibrancy of spring, offering a duet of tea and fruit flavors. The Sakura tea cake with cherry compote and Chocolate nibs financier with sakura cream joyfully evoke the tenderness of spring. Savory bites include the A5 Wagyu beef sushi, Negitoro taco, Tamagoyaki with sea urchin, and unique Sakura shrimp toast, all crafted with premium ingredients to paint a springtime culinary masterpiece to savor. Paired with a selection of coffee or tea, the pink-hued Japanese afternoon tea invites guests to savor the sensory romance of spring.

From now until May 28, Nagomi presents a delicate Sakura-themed feast to delight the senses.
From now until May 28, Nagomi presents a delicate Sakura-themed feast to delight the senses.

Hashtag: #GalaxyMacau

The issuer is solely responsible for the content of this announcement.

About Galaxy Macau Integrated Resort

Galaxy Macau™, The World-class Luxury Integrated Resort delivers the “Most Spectacular Entertainment and Leisure Destination in the World”. Developed at an investment of HK$43 billion, the property covers 1.1 million-square-meter of unique entertainment and leisure attractions that are unlike anything else in Macau. Eight award-winning world-class luxury hotels provide close to 5,000 rooms, suites and villas. They include Banyan Tree Macau, Galaxy Hotel™, Hotel Okura Macau, JW Marriott Hotel Macau, The Ritz-Carlton, Macau, Broadway Hotel, Raffles at Galaxy Macau and Andaz Macau. Unique to Galaxy Macau, the 75,000-square-meter Grand Resort Deck features the world’s longest Skytop Adventure Rapids at 575-meters, the largest Skytop Wave Pool with waves up to 1.5-meters high and 150-meters pristine white sand beach. Two five-star spas from Banyan Tree Spa Macau and The Ritz-Carlton Spa, Macau help guests relax and rejuvenate.

As the dining destination in Asia, Galaxy Macau offers a wide variety of gastronomic delights, exquisite experiences and ingredients of the finest quality with over 120 dining options from Michelin dining to authentic delicacies; Galaxy Promenade is the hottest shopping destination featuring the latest in fashion and curated experiences in Macau. Spanning over 100,000-square-meter, luxury flagship stores, lifestyle boutiques and our selection of labels are among the more than 200 world-renowned brands for a world-class shopping journey; Galaxy Cinemas, immersive thrills and luxurious comfort go hand in hand at Galaxy Cinemas. All 10 theaters are equipped with the latest audio-visual technology; CHINA ROUGE, one-of-a-kind cabaret lounge that evokes the glamor of Shanghai’s golden era with stylish entertainment and customizable surrounds; and Foot Hub, which presents the traditional art of reflexology for authentic relaxation and revitalization. For Authentic Macau Flavours and Vibrant Asian Experiences, Broadway Macau – just a 90-second walk via a bridge from Galaxy Macau, has over 35 Authentic Macau & Asian Flavours at Broadway Food Street. The 2,500-seat Broadway Theatre plays host to world-class entertainers and a diverse array of cultural events. Meeting, incentive and banquet groups are also catered to with a portfolio of unique venues in Galaxy Macau and an expert service team.

Galaxy International Convention Center (GICC) is the latest addition to the Group’s ever-expanding integrated resort precinct and will usher in a new era for the MICE industry in Macau. GICC is a world-class event venue featuring 40,000-square-meters of total flexible MICE, and the 16,000-seat Galaxy Arena – the largest indoor arena in Macau.

For more details, please visit , and .

Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction

By
Advertorial Desk
-

Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent Payments

  • Antev is developing Teverelix, A next generation GnRH Antagonist, as first in class market product for Acute Urinary Retention (AUR) and high CV risk Prostate Cancer

Philadelphia, Pennsylvania–(Newsfile Corp. – April 28, 2025) – Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus“) and Antev Ltd. (“Antev“), a UK-based late clinical-stage drug development company, announced today that they have entered into a binding letter of intent dated April 26, 2025 (the “Letter Agreement“) pursuant to which Medicus has agreed to acquire all of the issued and outstanding shares of Antev (the “Antev Shares“) on a share exchange basis (the “Transaction“).

Antev is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate.

Subject to the assumptions, qualifications, and conditions noted in the Letter Agreement, Medicus will negotiate and enter into a definitive agreement with Antev to acquire all issued and outstanding Antev Shares, on a fully diluted basis, in exchange for 2,666,600 (or approximately 19% in aggregate) of the issued and outstanding Medicus common shares (the “Consideration Shares“).

In addition to resale restrictions prescribed under applicable securities law, the Consideration Shares issuable to Antev shareholders will be subject to a 9-month staggered lock-up and an agreement granting certain voting rights in favor of Medicus management for a period of 36 months.

Antev shareholders will be entitled to receive up to approximately US$65 million in additional contingent consideration tied to potential future FDA Phase 2 and New Drug Application approvals, as more particularly described in the Letter Agreement.

The Transaction is expected to close before the end of June 2025, subject to the completion of satisfactory due diligence by Medicus, negotiation of definitive agreements, obtaining applicable corporate, regulatory and other third-party approvals and the fulfillment of customary closing conditions. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transactions will be consummated on the terms or timeframe currently contemplated, or at all.

“The LOI to acquire Antev represents strategic depth in our drug development program,” stated Dr. Raza Bokhari, Executive Chairman & CEO. “Teverelix, a next generation GnRH antagonist, is relatively derisked and is well positioned to become first in class product to prevent acute urinary retention recurrence and treat advanced prostate cancer in patients with high cardiovascular risk profile, collectively representing ~$6 Billion in potential market opportunity.”

1. Antev Acute Urinary Retention (AUR) Indication:

Teverelix is aiming to be the first-in-class indication product for preventing recurrence of acute urinary retention (AURr) in males 45 years or older who suffer from benign prostate hyperplasia (BPH). Antev has a US Food and Drug Administration (FDA) approved phase 2b study designed to randomize 390 men after a successful trial without catheterization (TWOC). 85% of nearly one million (1M) annual AUR episodes in the US occur in Men 60+ who suffer from enlarged prostate that manifests with age and frequently is followed by a recurrent episode within 6 months for approximately 30% of men, presenting a potential market opportunity of more than US$2B annually.

Antev planned Phase 2b Study Design in Acute Urinary Retention:

Randomized controlled double blinded study in 390 men after a successful TWOC in 60-70 sites in United States (US) and European Union (EU). The participants shall receive either single intramuscular (IM) or subcutaneous (SC) injection (90mg or 120mg) or placebo in addition to standard therapy. Primary endpoint is a composite of AURr, need for surgery or poor urinary flow metrics in the first 28 weeks, plus 24 weeks follow up.

2. Antev High Cardiovascular (CV) Risk Advanced Prostate Cancer (APC) Indication:

Teverelix is aiming to be the best-in-class indication product for hormone therapy for advanced prostate cancer (APC) patients with increased CV risk. Antev has a US Food and Drug Administration (FDA) approved phase 2b open label study designed to recruit 40 men with advanced prostate cancer. Antev is targeting a niche in patients with CV risk, aiming to provide an androgen deprivation therapy (ADT) option with potentially lower cardiac toxicity than conventional GnRH agonists. If approved, Teverelix could become the first hormone therapy labeled specifically for treating prostate cancer in patients with a history of cardiovascular disease. 300,000 to 500,000 men in the US are living with advanced stage prostate cancer, presenting a potential market opportunity of more than US$4B annually.

Antev planned Phase 2b Study Design in Advanced Prostate Cancer

Open label study in 40 men with advanced prostate cancer suitable for ADT. The participants shall receive a loading dose of 180mg IM plus x2 180mg SC (total 540mg), followed by x2 180mg (360mg) SC day 29 and every 6 weeks. The total duration of the treatment is 22 weeks. Primary endpoint is to confirm castration rate by day 29, sustaining to day 155, probability greater than 90%.

For further information, contact:
Carolyn Bonner, President
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com

About Medicus Pharma Ltd.:

Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets.

SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company submitted a Phase 2 IND clinical protocol to the FDA in January 2024 for a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003). In July 2024, an updated package was submitted to the FDA. The study design is to evaluate the efficacy of two dose of two dose levels (100 and 200 ug) of D-MNA compared to placebo (P-MNA) in sixty (60) subjects with nodular BCC. Patient recruitment is currently underway in nine sites across the United States. In April 2025, investigational review board increased the number of participants to Ninety (90) subjects. In March 2025, the company also announced a positively trending interim analysis for SKNJCT-003, demonstrating more the 60% clinical clearance. The interim analysis was conducted after more than 50% of the targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed.

About Antev Ltd.:

Antev is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for high CV-risk prostate cancer patients and patients with first acute urinary retention (AUR) episodes due to enlarged prostate.

Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

In January 2023, the U.S. Food and Drug Administration (FDA) reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

In December 2023, FDA approved the phase 2b study design in advanced prostate cancer covering 40 patients.

In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Transaction, including the entry into a definitive agreement in respect of the Transaction, the closing of the transaction or the timing thereof, the potential benefits of the Transaction, if consummated, including plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix, and the potential market opportunities related thereto, the results of the Company’s interim analysis, which may or may not correlate with the findings of the clinical study report that will be compiled following completion of the phase 2 study, the Company’s plans and expectations concerning, and future outcomes relating to, the submission and advancement of the phase 2 clinical protocol, the randomization of patients and size of the study, the Company’s intention to complete and submit an interim data analysis to the FDA and to request a Type C meeting and the timing thereof, the Company’s aim to fast fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), along with the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Readers are cautioned that the foregoing list is not exhaustive, and readers are encouraged to review the Annual Report accessible on the Company’s profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The issuer is solely responsible for the content of this announcement.

JCET Reports Q1 2025 Revenue Growth of 36.4% and Net Profit Growth of 50.4%

By
Advertorial Desk
-

Q1 2025 Financial Highlights:

  • Q1 revenue of RMB 9.34 billion, a 36.4% increase year-on-year, marking a record high for the same period.
  • Q1 net profit attributable to shareholders of the parent company of RMB 200 million, up 50.4% year-on-year.
  • Q1 net cash flow from operating activities of RMB 1.14 billion.
  • Q1 earnings per share of RMB 0.11, compared to RMB 0.08 in Q1 2024.

SHANGHAI, April 28, 2025 /PRNewswire/ — JCET Group (SSE: 600584), a leading global provider of integrated circuit (IC) back-end manufacturing and technology services, today announced its financial results for the first quarter of 2025. The company achieved revenue of RMB 9.34 billion in Q1 2025, a 36.4% increase year-on-year, marking a record high for the same period. Net profit attributable to owners of the parent was RMB 200 million, a 50.4% year-on-year increase.

In the first quarter of 2025, JCET maintained a steady and progressive business development, focusing on advanced technologies and key application markets. The company continued to optimize its business structure and improve its capacity layout and supply chain both domestically and internationally. During the reporting period, all business segments achieved significant year-on-year growth. In the field of computing electronics, JCET provides comprehensive solutions for global customers, meeting the increasing market demand, with revenue growing by 92.9% year-on-year. The automotive electronics business strengthened its turnkey service capabilities, with related revenue increasing by 66.0%. The industrial and medical electronics segment saw a revenue increase of 45.8% year-on-year. JCET remains committed to building a diversified and resilient supply chain, closely monitoring the international trade landscape, assessing and responding to potential impacts, and maintaining close communication with customers and suppliers.

With its comprehensive strength, JCET further solidified its position as a global semiconductor packaging leader, ranking in the “Semiconductor 30 2025” list published by Brand Finance in Q1.

Under the guidance of its strategic direction, JCET will continue to advance lean production, optimize product structure and capacity layout, and enhance its medium and long term profitability through technology innovation and economy of scale.

For more information, please refer to the JCET Q1 2025 Report

About JCET Group

JCET Group is the world’s leading integrated circuit back-end manufacturing and technology services provider. We offer a full range of turnkey solutions, including semiconductor package integration design and characterization, R&D, wafer probing, bumping, package assembly, final testing, and drop shipment to vendors worldwide.

Our comprehensive portfolio spans a broad range of semiconductor applications—including mobile, communication, computing, consumer, automotive, and industrial—delivered through advanced wafer-level packaging, 2.5D/3D packaging, System-in-Package solutions, and reliable flip chip and wire bonding technologies.

JCET Group has two R&D centers in China and Korea; eight manufacturing sites across China, Korea, and Singapore; and sales centers around the world, enabling close technology collaboration and efficient supply-chain manufacturing for our global customers.

Jianpu Technology Inc. Files 2024 Annual Report on Form 20-F

By
Advertorial Desk
-

BEIJING, April 28, 2025 /PRNewswire/ — Jianpu Technology Inc. (“Jianpu” or the “Company”) (OTCQB: AIJTY), a leading open financial technology platform in China, today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the Securities and Exchange Commission (the “SEC”) on April 28, 2025.

The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at http://www.sec.gov and on the Company’s investor relations website at http://ir.jianpu.ai. Hard copies of the annual report on 20-F can be provided, free of charge, to shareholders and ADS holders upon request by contacting ir@rong360.com. 

About Jianpu Technology Inc.

Jianpu Technology Inc. operates a leading open financial technology platform, under the Rong360 brand, connecting users with an extensive spectrum of financial products and other products and services. By leveraging cutting-edge digital technology, the Company offers intelligent and comprehensive search and recommendation results in a seamless, efficient, and secure manner to meet the needs of its diverse audience. The Company also enables financial and non-financial partners to enhance their efficiency and competitiveness by offering digital intelligence as a service, including data- and analytical-based risk management, intelligent marketing, and other integrated solutions and services. As the Company expands into FinTech+ ecosystem and broadens its global footprint, it will continue to innovate and solidify its influence in the space of financial technology and digital transformation. For more information, please visit http://ir.jianpu.ai.

For investor and media inquiries, please contact:

Jianpu Technology Inc.

(IR) Liting Lu, E-mail: IR@rong360.com
(PR) Amanda Hu, E-mail: Media@rong360.com
Tel: +86 (10) 6242 7068

Marriott International to Acquire the citizenM Brand

By
Advertorial Desk
-

Acquisition Supports Company’s Growth in Innovative Lifestyle Offerings

BETHESDA, Md., April 28, 2025 /PRNewswire/ — Today, Marriott International (Nasdaq: MAR) announced it has reached an agreement to acquire the lifestyle brand citizenM, a unique and innovative offering in the select-service segment. The transaction is expected to accelerate Marriott’s global expansion of its select-service and lifestyle lodging offerings, as the company continues to focus on expanding its portfolio to provide even more exciting options for guests and Marriott Bonvoy members around the world.

The citizenM global portfolio currently consists of 36 open hotels, comprising 8,544 rooms, across more than 20 cities spanning the U.S., Europe, and Asia Pacific, including gateway cities like New York, London, Paris, and Rome. The brand’s current pipeline includes three under-construction hotels totaling over 600 rooms that are anticipated to open by mid-2026, with the prospect of significant additional growth across Marriott’s global regions over the next decade.

The citizenM brand is known for its genuine service, tech-savvy in-hotel experience, highly efficient use of space, and focus on art and design. The brand, founded in 2008, caters to a growing demographic of value-conscious travelers looking for technology-driven accommodations with features like smart in-room design, indoor and outdoor common spaces featuring immersive artwork and local artifacts, comfortably appointed living rooms that serve as collaborative workspaces, creative meeting rooms, grab-and-go food and beverage options, and lively rooftop decks.

“As we continue to drive best-in-class experiences for travelers, today’s announcement builds upon Marriott’s commitment to enhance options for guests and Marriott Bonvoy members,” said Anthony Capuano, President and CEO of Marriott International. “We are thrilled to add citizenM as a unique, differentiated offering to our select-service brand portfolio as we continue to strengthen Marriott’s foothold in this valuable market segment around the world. Marriott has a proven track record of growing acquired brands significantly by leveraging our global development ecosystem, the benefits of our industry-leading affiliation cost structure, and the power of our award-winning Marriott Bonvoy loyalty platform.”

At closing of the transaction, Marriott will pay $355 million to acquire the brand and related intellectual property. Following closing, the citizenM portfolio will become part of Marriott’s system, with the hotels owned and leased by the seller subject to new long-term franchise agreements with Marriott. Stabilized fees for the open and under construction pipeline portfolio are anticipated to be approximately $30 million annually. The seller may also receive earn-out payments up to $110 million that are based on the future growth of the brand over a specified, multi-year timeframe. These payments would not begin until the fourth year following closing.

“We are very excited about our agreement with Marriott and look forward to this pivotal next step for our future growth. I envisage this relationship will greatly enhance citizenM’s global reach and brand impact. Marriott as an organization shares our values and culture, and I am confident in their deep commitment in continuing our brand’s DNA into the future,” said Rattan Chadha, Founder and Chairman of citizenM.

“I am excited about citizenM’s future with Marriott International. citizenM was created for frequent travelers, and Marriott’s distribution capabilities will allow us to welcome new modern guests. With the strength of Marriott’s development engine, we look forward to the prospect of many additional citizenM properties in new destinations around the world. We will continue to own our real estate and operate all our hotels. This relationship will allow us to work together to maximize returns,” said Lennert de Jong, CEO of citizenM.

The closing of the transaction is subject to various customary conditions, including U.S. regulatory approval.

Assuming closing of the transaction in 2025, Marriott now expects full year 2025 net rooms growth to approach 5 percent.

Morgan Stanley & Co. International plc and Eastdil Secured acted as financial advisors to the seller in this transaction.

Access the full gallery of high-resolution citizenM property images here.

NOTE ON FORWARD-LOOKING STATEMENTS
All statements in this press release are made as of April 28, 2025. Marriott undertakes no obligation to publicly update or revise these statements, whether as a result of new information, future events or otherwise. This press release contains “forward-looking statements” within the meaning of federal securities laws, including statements related to Marriott’s expectations regarding closing the transaction; future growth opportunities, plans and expectations; anticipated fees; the benefits of the transaction; net rooms growth in 2025; and similar statements concerning possible future events or expectations that are not historical facts. Marriott cautions you that these statements are not guarantees of future performance and are subject to numerous evolving risks and uncertainties that the company may not be able to accurately predict or assess, including failure to satisfy the conditions to the consummation of the transaction, including the receipt of required regulatory approvals; the effect of the announcement or pendency of the transaction on citizenM’s business; Marriott’s ability to successfully integrate and grow the citizenM brand after the transaction closes; and the other risk factors that Marriott describes in its U.S. Securities and Exchange Commission filings, including the company’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q. Any of these factors could cause actual results to differ materially from the expectations Marriott expresses or implies in this press release.

ABOUT MARRIOTT INTERNATIONAL, INC.
Marriott International, Inc. (Nasdaq: MAR) is based in Bethesda, Maryland, USA, and encompasses a portfolio of over 9,300 properties across more than 30 leading brands in 144 countries and territories. Marriott operates, franchises, and licenses hotel, residential, timeshare, and other lodging properties all around the world. The company offers Marriott Bonvoy®, its highly awarded travel platform. For more information, please visit our website at www.marriott.com, and for the latest company news, visit www.marriottnewscenter.com. In addition, connect with us on Facebook and @MarriottIntl on X and Instagram.

Marriott encourages investors, the media, and others interested in the company to review and subscribe to the information Marriott posts on its investor relations website at www.marriott.com/investor or Marriott’s news center website at www.marriottnewscenter.com, which may be material. The contents of these websites are not incorporated by reference into this press release or any report or document Marriott files with the U.S. Securities and Exchange Commission, and any references to the websites are intended to be inactive textual references only.

IRPR#1

JCET Reports Q1 2025 Revenue Growth of 36.4% and Net Profit Growth of 50.4%

By
Advertorial Desk
-

Q1 2025 Financial Highlights:

  • Q1 revenue of RMB 9.34 billion, a 36.4% increase year-on-year, marking a record high for the same period.
  • Q1 net profit attributable to shareholders of the parent company of RMB 200 million, up 50.4% year-on-year.
  • Q1 net cash flow from operating activities of RMB 1.14 billion.
  • Q1 earnings per share of RMB 0.11, compared to RMB 0.08 in Q1 2024.

SHANGHAI, April 28, 2025 /PRNewswire/ — JCET Group (SSE: 600584), a leading global provider of integrated circuit (IC) back-end manufacturing and technology services, today announced its financial results for the first quarter of 2025. The company achieved revenue of RMB 9.34 billion in Q1 2025, a 36.4% increase year-on-year, marking a record high for the same period. Net profit attributable to owners of the parent was RMB 200 million, a 50.4% year-on-year increase.

In the first quarter of 2025, JCET maintained a steady and progressive business development, focusing on advanced technologies and key application markets. The company continued to optimize its business structure and improve its capacity layout and supply chain both domestically and internationally. During the reporting period, all business segments achieved significant year-on-year growth. In the field of computing electronics, JCET provides comprehensive solutions for global customers, meeting the increasing market demand, with revenue growing by 92.9% year-on-year. The automotive electronics business strengthened its turnkey service capabilities, with related revenue increasing by 66.0%. The industrial and medical electronics segment saw a revenue increase of 45.8% year-on-year. JCET remains committed to building a diversified and resilient supply chain, closely monitoring the international trade landscape, assessing and responding to potential impacts, and maintaining close communication with customers and suppliers.

With its comprehensive strength, JCET further solidified its position as a global semiconductor packaging leader, ranking in the “Semiconductor 30 2025” list published by Brand Finance in Q1.

Under the guidance of its strategic direction, JCET will continue to advance lean production, optimize product structure and capacity layout, and enhance its medium and long term profitability through technology innovation and economy of scale.

For more information, please refer to the JCET Q1 2025 Report

About JCET Group

JCET Group is the world’s leading integrated circuit back-end manufacturing and technology services provider. We offer a full range of turnkey solutions, including semiconductor package integration design and characterization, R&D, wafer probing, bumping, package assembly, final testing, and drop shipment to vendors worldwide.

Our comprehensive portfolio spans a broad range of semiconductor applications—including mobile, communication, computing, consumer, automotive, and industrial—delivered through advanced wafer-level packaging, 2.5D/3D packaging, System-in-Package solutions, and reliable flip chip and wire bonding technologies.

JCET Group has two R&D centers in China and Korea; eight manufacturing sites across China, Korea, and Singapore; and sales centers around the world, enabling close technology collaboration and efficient supply-chain manufacturing for our global customers.

Health In Tech’s CEO Tim Johnson Discusses Company in 2025, Revenue Growth, and Healthcare on “The Street Reports Podcast” Listen Now!

By
Advertorial Desk
-

STUART, Fla., April 28, 2025 /PRNewswire/ — Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, is proud to share that CEO Tim Johnson was featured on The Street Reports Podcast.

Listen now: https://thestreetreports.com/health-in-technologys-nasdaq-hit-ceo-tim-johnson-discusses-company-in-2025-revenue-growth-and-healthcare-on-the-street-reports-podcast-listen-now/ 

The conversation highlighted the company’s 56% year-over-year revenue growth and its broader mission: restoring access, clarity, and control to those navigating today’s complex healthcare system.

Mr. Johnson offered an inside look at what drives Health In Tech’s innovation. A personal healthcare experience sparked his resolve to build a platform that empowers brokers, supports small businesses, and simplifies the process for individuals. Rather than layering new tech on top of outdated systems, Health In Tech started fresh, building a streamlined platform designed for speed, flexibility, and ease of use.

He described how brokers can now quote and bind health plans for employers in real time, creating a level of convenience and responsiveness that is innovative in the industry. Mr. Johnson also explained how the company has intentionally grown at a pace that preserves quality, ensuring it can scale without sacrificing what makes it special.

The episode is a powerful reminder that technology, when built with purpose, can transform more than just systems—it can restore dignity to the people inside them. Health In Tech remains committed to leading this change.

About Health In Tech

Health In Tech (Nasdaq: “HIT”) is an Insurtech platform company backed by third-party AI technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs. Learn more at healthintech.com.

About The Street Reports

The Street Reports discovering companies from “Wall Street 2 Bay Street” specializes in bringing relevant information on micro-cap, small-cap, and generally undervalued companies to the attention readers/listeners which maybe potential investors. 

Forward-Looking Statements

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Health In Tech’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech’s operations, results of operations, growth strategy and liquidity.

Investor Contact

Investor Relations:
ir@healthintech.com

 

1...3,3093,3103,311...6,420Page 3,310 of 6,420